Page 8 - Prostate Cancer Session

TheraP: Lu-177-PSMA vs cabazitaxel in 2L mCRPC

• Lu-177-PSMA is a radiolabelled small molecule

• Binds to PSMA receptor on cell surface

• Emits beta radiation (electrons) with a 1mm path length

• VISION study 2L mCRPC (docetaxel + ARSI): Lu-177-PSMA + SOC vs SOC [1]

• > 1 ARAT, 1-2 chemotherapy

• showed OS and PFS

• But while ARSI allowed, cabazitaxel, radium wasn’t allowed

• TheraP: cabazitaxel VS LuPSMA reported early outcomes in 2021 [2]

• Primary endpoint PSARR: 37 VS 67%

• 12mo PFS 3 vs 19%

• ORR 24 vs 49%

• Better tolerated. Gr3+ 53 vs 33%

[1] Sartor O et al., NEJM 2021; [2] Hofman MS et al., Lancet 2021